NVCT 7.70 Nuvectis Pharma, Inc.
| Range: | 5.85-12.1 | Vol Avg: | 87204 | Last Div: | 0 | Changes: | 0.84 |
| Beta: | 0.45 | Cap: | 0.14B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Feb 04 2022 | Empoloyees: | 13 | ||
| CUSIP: | 67080T108 | CIK: | 0001875558 | ISIN: | US67080T1088 | Country: | US |
| CEO: | Mr. Ron Bentsur M.B.A. | Website: | https://www.nuvectis.com | ||||
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow